8-K filing — Scienture Holdings, Inc. (SCNX)
Filed: 2026-08-20 AccNo: 0001493152-26-039474 Size: 344 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 12:23 PM
- Checked
- Aug 14, 2026, 12:23 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U.S. wholesale orders.
Read original at benzingaEXCLUSIVE: Scienture Commences Commercial Launch and Fulfillment of Initial Rezenopy Orders; Targets Execution Through End of 2026 By Expanding Payer Coverage, Product Access, and Institutional Adoption
Read original at benzinga